ReviewMolecular therapy : the journal of the American Society of Gene Therapy2009
New insights on adenovirus as vaccine vectors.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 258 citations in OpenAlex.
- Trial
- Bovine Adenovirus 3-Based Viral Vectors for Veterinary Vaccine Development: Progress, Limitations, and Future Directions.Veterinary sciences · 2026Review
- The immunogenicity and safety of adenoviral-based vaccines.Current opinion in allergy and clinical immunology · 2026Review
- Leish-F1 Multi-epitope Lentiviral Vaccine as a Novel Candidate Against Leishmania major in Balb/c Mice.Biochemical genetics · 2026Article
- Review
- Effects of cellular receptors on the vaccine efficacies of adenovirus vector-based vaccines following intramuscular and intranasal administration.Scientific reports · 2026Article
- Reprogramming the tumor microenvironment through vaccine strategies to improve clinical outcomes and guide future innovations.Discover oncology · 2026Review
- Article
- A recombinant adenoviral vector vaccine expressing the ORF2 capsid protein confers robust protection against chicken astrovirus infection.Veterinary research · 2026Article
- A Novel Bicistronic Adenovirus Vaccine Elicits Superior and Comprehensive Protection Against BVDV.Microorganisms · 2026Article
- Article
- Systemic and Mucosal Immune Responses Induced by Adenoviral-Vectored Consensus H5 Influenza A Vaccines in Mice and Swine.Vaccines · 2025Article
- Cancer vaccines: an update on recent achievements and prospects for cancer therapy.Clinical and experimental medicine · 2024Review
- Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.Journal of microbiology (Seoul, Korea) · 2024Review
- Possibilities and efficiency of MSC co-transfection for gene therapy.Stem cell research & therapy · 2024Review
- Conditional splicing system for tight control of viral overlapping genes.Journal of virology · 2024Article
- Construction and application of adenoviral vectors.Molecular therapy. Nucleic acids · 2023Review
- Gene Therapy for Inherited Hearing Loss: Updates and Remaining Challenges.Audiology research · 2023Review
- Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity.Vaccines · 2023Article
- Gene Therapy for Regenerative Medicine.Pharmaceutics · 2023Review
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Adenovirus (Ad) vectors were initially developed for treatment of genetic diseases. Their usefulness for permanent gene replacement was limited by their high immunogenicity, which resulted in rapid elimination of transduced cells through induction of T and B cells to antigens of Ad and the transgene product. The very trait that excluded their use for sustained treatment of genetic diseases made them highly attractive as vaccine carriers. Recently though results showed that Ad vectors based on common human serotypes, such as serotype 5, may not be ideal as vaccine carriers. A recently conducted phase 2b trial, termed STEP trial, with an AdHu5-based vaccine expressing antigens of human immunodeficiency virus 1 (HIV-1) not only showed lack of efficacy in spite of the vaccine's immunogenicity, but also suggested an increased trend for HIV acquisition in individuals that had circulating AdHu5 neutralizing antibodies prior to vaccination. Alternative serotypes from humans or nonhuman primates (NHPs), to which most humans lack pre-existing immunity, have been vectored and may circumvent the problems encountered with the use of AdHu5 vectors in humans. In summary, although Ad vectors have seen their share of setbacks in recent years, they remain viable tools for prevention or treatment of a multitude of diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.